4//SEC Filing
Patel Nikin 4
Accession 0001209191-18-046788
CIK 0000821995other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 4:20 PM ET
Size
29.8 KB
Accession
0001209191-18-046788
Insider Transaction Report
Form 4
Patel Nikin
DirectorCEO, Molecular Profiles
Transactions
- Exercise/Conversion
Common Stock
2018-08-14$7.90/sh+40,000$316,000→ 264,784 total - Exercise/Conversion
Common Stock
2018-08-14$5.15/sh+53,000$272,950→ 327,784 total - Exercise/Conversion
Common Stock
2018-08-14$5.56/sh+32,000$177,920→ 409,784 total - Exercise/Conversion
Common Stock
2018-08-14$7.05/sh+32,000$225,600→ 441,784 total - Tax Payment
Common Stock
2018-08-14$11.50/sh−123,823$1,423,965→ 317,961 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−10,000→ 0 totalExercise: $4.05Exp: 2024-04-11→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−50,000→ 0 totalExercise: $7.82Exp: 2023-02-19→ Common Stock (50,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−32,000→ 0 totalExercise: $7.05Exp: 2021-03-10→ Common Stock (32,000 underlying) - Exercise/Conversion
Common Stock
2018-08-14$4.05/sh+10,000$40,500→ 274,784 total - Exercise/Conversion
Common Stock
2018-08-14$7.82/sh+50,000$391,000→ 377,784 total - Award
Common Stock
2018-08-14$11.50/sh−10,500$120,750→ 328,461 total - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−40,000→ 0 totalExercise: $7.90Exp: 2025-02-09→ Common Stock (40,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−53,000→ 0 totalExercise: $5.15Exp: 2024-03-03→ Common Stock (53,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2018-08-14−32,000→ 0 totalExercise: $5.56Exp: 2022-02-11→ Common Stock (32,000 underlying)
Footnotes (3)
- [F1]123,823 shares at $11.50 per share were withheld and surrendered to the Issuer as part of a net cashless exercise in connection with the merger.
- [F2]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
- [F3]This option vests automatically upon a change in control, which occurred when the tender offer contemplated by the Merger Agreement was completed on August 14, 2018. This option was exercised immediately prior to the Effective Time of the merger.
Documents
Issuer
JUNIPER PHARMACEUTICALS INC
CIK 0000821995
Entity typeother
Related Parties
1- filerCIK 0001587273
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 4:20 PM ET
- Size
- 29.8 KB